LUCAS SVETLANA (Chief Business Officer) purchased 3K shares of SCRIBE THERAPEUTICS, INC. on the open market
Open‑market purchase worth $45.0K. The strongest form of insider conviction signal.
P · 1 purchase
Filed: 7/28/2026ACC: 0001781292-26-000007
Officer· Chief Business Officer
Since Jul 2026
+231.40K
Net shares
Net buyer
$45.0K
Total acquired
1
Open market trades
1B · 0S
4
Total transactions
231.40K acquired
Non-Derivative Transactions1
Common Stock
Indirect
Shares
+3K
Price / share
$15.00
Trade value
$45K
% of position
New position
7/23/2026
0.00→3K
Total
Net shares
+3K
Net value
$45K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Indirect | 7/23/2026 | P · Purchase | +3K | $15.00 | $45K | New position | 0.00 | 3K |
| Total | +3K | $45K | ||||||
Derivative Transactions3
Stock Option (Right to Buy)
Direct
Converts to
Common Stock
9.55K shares
Shares
+9.55K
Strike price
19.13
Held after
9.55K
Exercisable
—
3/13/2026
Stock Option (Right to Buy)
Direct
Converts to
Common Stock
109.43K shares
Shares
+109.43K
Strike price
15
Held after
109.43K
Exercisable
—
7/23/2026
Performance-based Stock Option (Right to Buy)
Direct
Converts to
Common Stock
109.43K shares
Shares
+109.43K
Strike price
15
Held after
109.43K
Exercisable
—
7/23/2026
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy) Direct | Common Stock9.55K shares | 3/13/2026 | A · Award | +9.55K | 19.13 | — | 9.55K |
| Stock Option (Right to Buy) Direct | Common Stock109.43K shares | 7/23/2026 | A · Award | +109.43K | 15 | — | 109.43K |
| Performance-based Stock Option (Right to Buy) Direct | Common Stock109.43K shares | 7/23/2026 | A · Award | +109.43K | 15 | — | 109.43K |